Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Дерматологические реакции при проведении противоопухолевой терапии

Список литературы

  1. Lacouture M.E.Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6 (10):803–812.
  2. Hu J.C., Sadeghi P., Pinter-Brown L.C., Yashar S., Chiu M.W.Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56(2):317–326.
  3. Trueb, R. M. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care 2010; 4(4): 281-284.
  4. Balagula Y., Garbe C., Myskowski PL., Hauschild A., Rapoport B.L., Boers-Doets C.B., Lacouture M.E. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int. J. Dermatol. 2011; 50 (2): 129–146. DOI: 10.1111/j.1365- 4632.2010.04791.x.
  5. Minisini A.M., Tosti A., Sobrero A.F., Mansutti M., Piraccini B.M., Sacco C., et al. Taxane-induced nail changes: incidence, clinical presentation and outcome, Ann Oncol, 2003; 14: 333-337.
  6. Eames T., Grabein B., Kroth J., Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24 (8):958–960.
  7. Fitzpatrick J.E. The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 1993; 20: 1-14.
  8. Cox G.J., Robertson D.B. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol 1986; 122: 1413-1414.
  9. Lotem M., Hubert A., Lyass O., Goldenhersh M.A., Ingber A., Peretz T., Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136: 1475-1480.
  10. Asgari M.M., Haggerty J.G., McNiff J.M., Milstone L.M., Schwartz P.M. Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol 1999; 26: 287-294.
  11. Balagula Y., Wu S., Su X., Lacouture M.E. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 2011; 22 (11):2366–2374. doi:10.1093/annonc/mdr016
  12. Amgen Inc. VectibixTM [prescribing information]. Accessed February 19, 2007 http://www.vectibix.com/prescribing_information/prescribing_information.html
  13. Liang R.F., Zheng L.L. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials. Drug Des Devel Ther. 2015; 9: 4471-4478. doi: 10.2147/DDDT.S85178.
  14. OSI Pharmaceuticals Inc. Tarceva® [prescribing information]. 2007 Accessed February 19, 2007 http://www.gene.com/gene/products/information/oncology/tarceva/insert.jsp
  15. Thatcher N., Chang A., Parikh P. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: Results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527– 1537.
  16. Lacouture M.E., Schadendorf D., Chu C.Y., Uttenreuther-Fischer M., Stammberger U., O’Brien D., Hauschild A. ) Dermatologic adverse events associated with afatinib: an oral ErbB family blocker, Expert Review of Anticancer Therapy 2013; 13(6), 721-728, DOI: 10.1586/era.13.30
  17. Chu, D., Lacouture M.E., Fillos T.,Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47(2): 176-186.
  18. Lee W. J., Lee J.L., Chang S. E., Lee M. W., Kang Y. K., Choi J. H., Moon K. C., Koh J. K. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161(5): 1045-1051.
  19. Rosenbaum, S. E., Wu S., Newman M.A., West D.P., Kuzel T., Lacouture M.E. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib (Structured abstract). Supportive Care in Cancer 2008; 16, 557-566.
  20. Perez-Soler R. Delord J.P.; Halpern A. et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10: 345-356.
  21. Minisini A.M., Tosti A., Sobrero A.F., Mansutti M., Piraccini B.M., Sacco C., et al. Taxane-induced nail changes: incidence, clinical presentation and outcome, Ann Oncol, 2003; 14: 333-337.
  22. Capriotti K., Capriotti J. A., Lessin S., Wu S., Goldfarb S., Belum V.R., Lacouture M. E. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol 2015;173(3):842-5. doi: 10.1111/bjd.13743.
  23. Betrian S., Gomez-Roca C., Vigarios E., Delord J.P., Sibaud V. Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors. JAMA Dermatol 2017;153(7):723–5.
  24. Garden B.C., Wu S., Lacouture M.E. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012; 67(3):400–408. doi: 10.1016/j.jaad.2011.10.009.
  25. Trueb R. M. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care 2010; 4(4): 281-284.
  26. Belum V.R., Marulanda K., Ensslin C., Gorcey L., Parikh T., Wu S., Busam K.J., Gerber P.A. Lacouture M.E. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015;26(12):2496-502. doi: 10.1093/annonc/mdv390.
  27. Belum, V. R., Wu S., Lacouture M.E.Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.Invest New Drugs 2013; 31(4): 1078-1086.
  28. Wardley, A. M., Pivot X., Morales-Vasquez F., Zetina L.M., de Fatima Dias Gaui M., Reyes D.O., Jassem J., Barton C., Button P., Hersberger V., Torres A.A. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28(6): 976-983.
  29. Nagore E., Insa A., Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1(4): 225-234.
  30. Lorusso, D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007; 18(7): 1159-1164.
  31. Sehouli J., Oskay-Ozcelik G., Kuhne J., Stengel D., Hindenburg H. J., Klare P., Heinrich G., Schmalfeldt B., Mertens H., Camara O., Lichtenegger W. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial." Ann Oncol 2006; 17(6): 957-961.
  32. Galimont-Collen A. F., Vos L. E., Lavrijsen A. P. et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor(EGFR) inhibitors. Eur J Cancer 2007;43(5):845–51. DOI: 10.1016/j.ejca.2006.11.016. PMID: 17289377.
  33. CTCAE 4.03. Common Terminology Criteria for. Adverse Events (CTCAE). //evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
  34. Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16(9):1425–33. DOI: 10.1093/annonc/mdi279. PMID: 16012181.
  35. Robert C., Soria J. C., Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6(7):491–500. DOI: 10.1016/S1470-2045(05)70243-6. PMID: 15992698.
  36. Burtness B., Anadkat M., Basti S. et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009;7(Suppl 1):S5–21.PMID: 19470276.
  37. Agero A. L., Dusza S. W., Benvenuto-Andrade C. et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55(4):657–70. DOI: 10.1016/j. jaad. 2005.10.010. PMID: 17010747.
  38. Grenader T., Gipps M., Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9(1):59–60. DOI: 10.3816/CLC.2008.n.010. PMID: 18282360.
  39. Ocvirk J., Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. JEADV 2010; 24:453–459.
  40. Osio A., Mateus C., Soria J.C., Massard C., Malka D., Boige V., Besse B., Robert C. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009ж 161(3):515–521.
  41. Piraccini B.M., Tosti A. Drug-induced nail disorders: incidence, management and prognosis, Drug Saf, 1999;. 21: 187-201.
  42. Eames T., Grabein B., Kroth J., Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24 (8):958–960.
  43. Garden B.C., Wu S., Lacouture M.E.. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67(3):400–408. doi: 10.1016/j.jaad.2011.10.009.
  44. Lacouture M.E., Mitchell E.P., Piperdi B., Pillai M.V., Shearer H., Iannotti N., Xu F., Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28(8):1351–1357.
  45. Scope A, Agero A.L., Dusza S.W., Myskowski P.L., Lieb J.A., Saltz L., Kemeny N.E., Halpern A.C. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25 (34):5390–5396.
  46. Petrelli F., Borgonovo K., Cabiddu M., Coinu A., Ghilardi M., Lonati V., Barni S. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analyis. Br J Dermatol 2016; 175(6):1166–1174.
  47. Interventions for impetigo. Cochrane Database Syst Rev. 2012 Jan 18; 1:CD003261.
  48. Доксициклин (Doxycycline) инструкция по применению препарата http://www.vidal.ru/drugs/doxycycline 13306" arget="_blank"><b>Доксициклин</b>.
  49. Raimondi A., Corallo S., Lonardi S., Antoniotti C., Rimassa L. t al. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. Supportive Care in Cancer 2021; 29, 3971–3980.
  50. Reguiai Z., Bachet J.B., Bachmeyer C., Peuvrel L., Beylot-Barry M. et al. Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Support Care Cancer 2012; 20:1395–1404.
  51. Potthoff K, Hofheinz R, Hassel JC et al.) Interdisciplinary management of EGFR- inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22:524–535.
  52. Melosky B., Burkes R., Rayson D., Alcindor T., Shear N., Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16(1):16–26.
  53. Freites-Martinez A., Lacouture M.E. Dermatologic Adverse Events. The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer International Publishing AG, part of Springer Nature. 2018. p.597-620.
  54. Королева И. А., Болотина Л. В., Гладков О. А., Горбунова В. А., Круглова Л. С., Манзюк Л. В. и соавт. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2020 (том 10).42
  55. Шатохина Е. А., Круглова Л. С. Акнеподобная сыпь – кожная токсическая реакция на применение ингибиторов EGFR. Опухоли головы и шеи 2018;8(4):48–55.
  56. Scope A., Lieb J.A., Dusza S.W. et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009; 61:614–620.
  57. Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicinrelated palmar-plantar erythrodysesthesia (‘handfoot’ syndrome). Ann Oncol. 2007;18(7):1159–64.
  58. Wolf S. L., Qin R., Menon S.P., Rowland K.M., Thomas Jr. S., Delaune R., et al.rg and C. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.J Clin Oncol 2010; 28(35): 5182-5187.
  59. Hofheinz R. D., Gencer D., Schulz H., Stahl M., Hegewisch-Becker S., et al. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.J Clin Oncol 2010 33(22): 2444-2449.
  60. Ren Z., Zhu K., Kang H., Lu M., Qu Z., et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33(8): 894-900.
  61. Nagore E., Insa A., Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome: incidence, recognition and management. Am J Clin Dermatol. 2000; 1: 225–34.
  62. Sil A., Das N.K. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma. Indian J Pharmacol 2014; 46: 334–336.
  63. Bos W.E., Nijsten T.E., de Jonge M.J., Hamberg A.P. Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome. Arch Dermatol 2012; 148: 546– 547.
  64. Echeverria B., Llombart B., Botella-Estrada R., Guillen C. Palmoplantar cutaneous reaction to sorafenib [article in Spanish]. Actas Dermosifiliogr 2009; 100: 736–737.
  65. Vanneste L., Wolter P., Van den Oord J.J., et al. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol 2014; 29: 61–68
  66. Anderson R., Jatoi A., Robert C., et al. . Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14: 291–302.
  67. Milano G., Mortier L., Digue L., et al. Hand-foot syndrome and sorafenib [Article in French]. Bull Cancer 2009; 96: 191–197.
  68. Lacouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand- foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001–1011.
  69. Shinohara N., Nonomura N., Eto M., Kimura G., Minami H., Tokunaga S., Naito S. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol 2014; 25(2): 472-476.
  70. Shin H., Jo S.J., Kim do H., Kwon O., Myung S.K. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer 2015;136(5): E442-454.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*